}}}\) method normalizing to housekeeping genes (TBP or PPIA). All primer sequences are provided in Supplementary Table 9. All RT–qPCR experiments were ...

The FDA’s approval of an mRNA flu shot presents a new, long-awaited option—and raises big questions about the future of flu vaccines. On August 5, the US Food and Drug Administration approved ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Generative AI is rapidly transforming software development, with adoption of AI coding ...

This article originally appeared on the Bloomberg School of Public Health website. An mRNA flu vaccine is on its way. On Aug. 5, the U.S. Food and Drug Administration approved Moderna's mFLUSIVA, the ...

Even if you only use an AI chatbot occasionally or not at all, there's a good chance you've run into the term vibe coding. For the uninitiated, it's a form of software development that involves using ...

An estimated 2.1 million new cancer cases will be diagnosed in the United States this year and an estimated 626 thousand will die, according to the American Cancer Society. However, there may be hope ...

Share on Pinterest Moderna’s new mRNA flu vaccine has been approved by the FDA for adults ages 50 years and older. FatCamera, E+/Getty Images The Food and Drug Administration (FDA) has approved ...

Professor Jeremy Sanford chairs the Department of Molecular, Cell, & Developmental Biology and co-directs the RNA Center at UC Santa Cruz. The U.S. Food and Drug Administration’s approval of the first ...

Moderna is touting a "landmark moment" in its experimental melanoma treatment, saying its vaccine could help prevent the deadly skin cancer from returning or spreading. The groundbreaking clinical ...

Skin cancer is both common and deadly. Pharmaceutical companies are racing to develop new therapies to target melanoma, a form of skin cancer, using mRNA technology. And now, in a “landmark” trial, ...

Moderna and Merck have announced that a personalised mRNA cancer vaccine called Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field ...

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the ...